Skip to Main Content

Paper Details

Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Transpl Infect Dis
26
2022

Datasets

Release 1.2